Up next

Autoplay

Belzutifan cabozantinib combo shows durable anti-tumour effect at phase II for ccRCC

1 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

Dr Choueiri talks to ecancer at ESMO 2023 about the phase II LITESPARK-003 study, which
has so far indicated that the combination of belzutifan and cabozantinib is a promising treatment for advanced clear cell renal cell carcinoma.

The study found the treatment option to be effective in both first-line and subsequent-line settings and showed durable anti-tumour activity with a safety profile consistent with prior observations.

These results further support the use of an HIF-2α inhibitor and VEGFR-TKI combination for treating advanced ccRCC.

Show more
0 Comments sort Sort By

Up next

Autoplay